Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CRMD

CorMedix Inc

Nov 07 • 10:09AM ET

10.67

-0.11 -1.02 %

Healthcare • Biotechnology • USA • NASD

Peers: BCRX ADMA ANIP CTSO RMTI AMRX CRVS CLSD XTNT NAII

| Held by: VTI IWM VXF IWO PBE IBB VTWO SCHA XPH SFLO

Scroll to Statements

Index	RUT	P/E	14.29	EPS (ttm)	0.75	Insider Own	10.44%	Shs Outstand	74.62M	Perf Week	-4.13%
Market Cap	835.98M	Forward P/E	4.29	EPS next Y	2.49	Insider Trans	-1.67%	Shs Float	70.17M	Perf Month	-3.00%
Enterprise Value	645.71M	PEG	-	EPS next Q	0.63	Inst Own	45.34%	Short Float	23.06%	Perf Quarter	5.96%
Income	51.16M	P/S	6.88	EPS this Y	791.90%	Inst Trans	18.22%	Short Ratio	4.61	Perf Half Y	-8.49%
Sales	121.48M	P/B	3.61	EPS next Y	19.75%	ROA	32.97%	Short Interest	16.18M	Perf YTD	31.73%
Book/sh	2.96	P/C	4.38	EPS next 5Y	-	ROE	38.35%	52W High	17.43 -38.78%	Perf Year	5.12%
Cash/sh	2.43	P/FCF	27.49	EPS past 3/5Y	25.91% 29.80%	ROIC	23.16%	52W Low	5.60 90.54%	Perf 3Y	261.69%
Dividend Est.	-	EV/EBITDA	12.93	Sales past 3/5Y	510.62% 173.65%	Gross Margin	95.62%	Volatility	5.99% 5.56%	Perf 5Y	113.40%
Dividend TTM	-	EV/Sales	5.32	EPS Y/Y TTM	184.19%	Oper. Margin	40.60%	ATR (14)	0.62	Perf 10Y	-15.98%
Dividend Ex-Date	-	Quick Ratio	7.52	Sales Y/Y TTM	14970.29%	Profit Margin	42.11%	RSI (14)	42.92	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.82	EPS Q/Q	212.26%	SMA20	-3.57%	Beta	1.32	Target Price	19.43
Payout	-	Debt/Eq	0.00	Sales Q/Q	4829.40%	SMA50	-8.25%	Rel Volume	0.52	Prev Close	10.78
Employees	65	LT Debt/Eq	0.00	Earnings	Nov 12 BMO	SMA200	-4.59%	Avg Volume	3.51M	Price	10.67
IPO	May 13, 2010	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.00% 13.29%	Trades		Volume	262,367	Change	-1.02%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy	$14
Jun-30-25	Initiated	H.C. Wainwright	Buy	$20
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Mar-07-25	Initiated	Leerink Partners	Outperform	$18
Jan-13-25	Initiated	D. Boral Capital	Buy	$15
Aug-26-24	Initiated	Rodman & Renshaw	Buy	$13
Aug-10-23	Initiated	RBC Capital Mkts	Outperform	$6
Feb-17-21	Initiated	Needham	Buy	$31
Sep-29-20	Initiated	JMP Securities	Mkt Outperform	$22
Sep-21-20	Initiated	Truist	Buy	$20
Dec-18-19	Initiated	B. Riley FBR	Buy	$48
Mar-26-19	Reiterated	H.C. Wainwright	Buy	$3 → $15
Dec-06-18	Initiated	ROTH Capital	Buy	$6
Sep-25-17	Reiterated	H.C. Wainwright	Buy	$3 → $4
Aug-10-17	Reiterated	Rodman & Renshaw	Buy	$5 → $3
May-05-17	Reiterated	Rodman & Renshaw	Buy	$6 → $5
Nov-11-16	Reiterated	FBR & Co.	Outperform	$6 → $4
Mar-17-16	Reiterated	FBR Capital	Outperform	$7 → $6
Mar-03-16	Initiated	FBR Capital	Outperform	$7
Nov-16-15	Reiterated	ROTH Capital	Neutral	$2.75 → $2.50

Show Previous Ratings

Nov-06-25 01:59PM	Revolution Medicines Posts Wider-Than-Expected Loss in Q3, Sales Nil (Zacks)
10:50AM	JAZZ Beats on Q3 Earnings & Sales, Narrows '25 Sales View (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
Nov-05-25 02:18PM	Perrigo Q3 Earnings Beat, Sales Miss, Stock Falls on '25 View Cut (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:11AM	Loading…
09:11AM	Bet on 5 Top-Ranked Stocks With Rising P/E (Zacks)
Nov-04-25 12:00PM	All You Need to Know About CorMedix (CRMD) Rating Upgrade to Strong Buy (Zacks)
07:22AM	New Strong Buy Stocks for November 4th (Zacks)
Oct-31-25 08:30AM	CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 (GlobeNewswire)
Oct-30-25 02:05PM	CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
12:41PM	MRK Beats Q3 Earnings Estimates, Narrows 2025 Sales View, Stock Down (Zacks)
12:08PM	Amarin's Q3 Earnings Lag Estimates, Revenues Beat, Stock Down (Zacks)
Oct-29-25 11:24AM	United Therapeutics Q3 Earnings Beat Estimates, Revenues Miss Mark (Zacks)
11:18AM	RGEN'S Q3 Earnings Beat Estimates, Revenues Surge Y/Y, Stock Down (Zacks)
08:52AM	4 High-Earnings Yield Value Picks Ahead of Potential Fed Rate Cut (Zacks)
10:40AM	Loading…
Oct-28-25 10:40AM	Should Investors Buy CorMedix Stock Ahead of Q3 Earnings Report? (Zacks)
Oct-23-25 08:30AM	CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath (GlobeNewswire)
Oct-22-25 04:05PM	Halper Sadeh LLC Encourages CorMedix Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
10:18AM	SNY's Efdoralprin Alfa Meets Key Endpoints in Rare Disease Study (Zacks)
Oct-21-25 12:20PM	Earnings Estimates Rising for CorMedix (CRMD): Will It Gain? (Zacks)
09:55AM	Wall Street Analysts See a 68.59% Upside in CorMedix (CRMD): Can the Stock Really Move This High? (Zacks)
09:15AM	CorMedix (CRMD) Surges 19.5%: Is This an Indication of Further Gains? (Zacks)
08:30AM	Talphera Announces the Appointment of Joe Todisco to Board of Directors (PR Newswire)
Oct-20-25 10:10AM	How Will DefenCath Aid CRMD's Top Line in the Upcoming Q3 Results? (Zacks) +19.45%
07:30AM	CorMedix Inc. Announces Preliminary Third Quarter 2025 Results and Raises 2025 Net Revenue Guidance (GlobeNewswire)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks)
Oct-14-25 10:38AM	CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip? (Zacks)
08:23AM	FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months (Zacks)
Oct-07-25 10:32AM	Will CorMedix's DefenCath Edge Last If Bigger Heparin Rivals Close In? (Zacks)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
08:44AM	Loading…
Oct-03-25 08:44AM	ILMN Stock Set to Benefit From the Launch of New BioInsight Division (Zacks)
08:21AM	ANGO Stock Gains Following Q1 Earnings Beat, Gross Margin Improves (Zacks)
Sep-29-25 08:30AM	CorMedix Announces Completion of Enrollment in Phase III ReSPECT Clinical Trial for REZZAYO (GlobeNewswire)
Sep-26-25 10:05AM	CDTX Stock Soars 218% YTD on Positive Updates From Influenza Program (Zacks)
Sep-25-25 11:07AM	QURE Stock Skyrockets on Meeting Goals in Huntington's Disease Study (Zacks)
10:50AM	ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure (Zacks)
Sep-24-25 11:06AM	REPL Stock Plunges 54% in 3 Months After FDA Rejects Skin Cancer Drug (Zacks)
Sep-23-25 10:44AM	CRMD vs. MIRM: Which Specialized Biotech Stock is the Better Pick? (Zacks)
Sep-22-25 12:03PM	SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU (Zacks)
11:29AM	FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing (Zacks)
Sep-18-25 10:54AM	Can CorMedix's Melinta Deal Fuel Growth Via Portfolio Diversification? (Zacks) +5.13%
09:17AM	Biogen Gets EU Nod for First Postpartum Depression Drug (Zacks)
Sep-17-25 02:27PM	Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD) (Insider Monkey)
09:38AM	INCY Announces New Late-Stage Data on Skin Disease Drug (Zacks)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
10:27AM	CorMedix Rallies 60% YTD: Is This an Indication to Buy the Stock? (Zacks)
09:52AM	Zoetis Gains CVMP Backing for Portela, Eyes EU Approval in Cat OA Pain (Zacks)
Sep-12-25 11:36AM	JNJ Seeks EU Approval for Oral Psoriasis Drug Icotrokinra (Zacks)
11:13AM	RAPP Stock Soars 62% in a Week on Meeting Phase II Epilepsy Study Goal (Zacks)
Sep-11-25 10:40AM	TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA (Zacks)
Sep-09-25 11:12AM	RARE Reports Positive Long-Term Data From Metabolic Disorder Study (Zacks)
09:55AM	CorMedix (CRMD) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Sep-08-25 08:30AM	Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market (PR Newswire)
08:30AM	CorMedix Announces Strategic Minority Investment in Talphera (GlobeNewswire)
Sep-04-25 02:56PM	Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability (Insider Monkey) -6.57%
11:06AM	IMVT Stock Up 11% on Upbeat Batoclimab Hyperthyroidism Study Results (Zacks)
Sep-03-25 10:02AM	Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results (Zacks) -6.42%
09:55AM	Wall Street Analysts Think CorMedix (CRMD) Could Surge 32.04%: Read This Before Placing a Bet (Zacks)
09:49AM	Editas Nominates EDIT-401 as Lead In Vivo Therapy for High Cholesterol (Zacks)
Sep-02-25 10:18AM	Is DefenCath Sufficient to Support CorMedix's Long-Term Growth Path? (Zacks)
07:30AM	CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team (GlobeNewswire)
Sep-01-25 10:50AM	ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win (Zacks)
10:31AM	Biogen Secures FDA Nod for Subcutaneous Maintenance Dosing of Leqembi (Zacks)
Aug-29-25 11:13AM	J&J Ends Imaavy Development in Rheumatoid Arthritis Post Study Failure (Zacks)
10:38AM	OTLK Stock Crashes 54% as FDA Issues Second CRL for Eye Disease Drug (Zacks)
05:05AM	CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio (Insider Monkey)
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
08:30AM	CorMedix to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-26-25 11:16AM	Catalyst Pharmaceuticals Settles Firdapse Patent Litigation With Lupin (Zacks)
09:17AM	IOVA Stock Drops 6% on $350M Common Stock Offering (Zacks)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
Aug-22-25 09:55AM	GILD Stock Slips as CVS Health Excludes New HIV Drug Yeztugo (Zacks)
Aug-21-25 09:40AM	Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-18-25 09:55AM	Wall Street Analysts Believe CorMedix (CRMD) Could Rally 45.63%: Here's is How to Trade (Zacks)
Aug-14-25 12:20PM	Why CorMedix (CRMD) Might be Well Poised for a Surge (Zacks)
11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-13-25 12:31PM	Theravance's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y (Zacks) +5.04%
12:17PM	Time to Buy Eli Lilly and Other Undervalued Healthcare Stocks? (Zacks)
Aug-12-25 11:43AM	SMMT Q2 Loss Wider Than Expected, Ivonescimab Studies in Focus (Zacks) +14.20%
10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
10:16AM	Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
09:11AM	Needham Maintains a Buy Rating on CorMedix (CRMD) With a $20 PT (Insider Monkey)
08:18AM	DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 (Zacks)
Aug-08-25 12:47PM	IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi (Zacks)
11:45AM	Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y (Zacks)
11:19AM	Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus (Zacks)
11:02AM	Cormedix Inc (CRMD) Q2 2025 Earnings Call Highlights: Strategic Acquisition and Positive ... (GuruFocus.com)
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
05:25AM	CorMedix signs agreement to acquire Melinta for $300m (Pharmaceutical Technology)
Aug-07-25 11:20AM	MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View (Zacks) -9.54%
11:14AM	NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View (Zacks)
11:00AM	Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates (Zacks)
10:49AM	CorMedix to Buy Melinta Therapeutics for $300 Million (The Wall Street Journal)
10:08AM	Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:04AM	Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth (Zacks)
08:25AM	CorMedix (CRMD) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
08:17AM	ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum (Zacks)
07:27AM	CorMedix: Q2 Earnings Snapshot (Associated Press Finance)
07:10AM	Melinta Therapeutics Announces Strategic Acquisition by CorMedix, Underscoring Its Portfolio Value and Industry Leadership (Business Wire)
07:00AM	CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings (GlobeNewswire)

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Erin Mistry	Former Officer	Nov 06 '25	Proposed Sale	10.97	13,908	152,503		Nov 06 04:27 PM
Kaplan Myron	Director	Oct 23 '25	Buy	11.02	25,000	275,500	201,034	Oct 27 09:30 PM
Duncan Gregory Scott	Director	Sep 16 '25	Option Exercise	8.32	13,333	110,931	38,333	Sep 18 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Option Exercise	3.55	10,000	35,500	50,250	Sep 16 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Sale	13.13	10,000	131,300	40,250	Sep 16 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Option Exercise	3.47	50,000	173,500	559,496	Sep 12 09:45 PM
Todisco Joseph	Chief Executive Officer	Sep 12 '25	Sale	13.00	50,000	650,000	509,496	Sep 12 09:45 PM
DUNTON ALAN W	Director	Sep 12 '25	Proposed Sale	13.10	10,000	130,950		Sep 12 04:37 PM
Todisco Joseph	Officer	Sep 12 '25	Proposed Sale	12.97	50,000	648,569		Sep 12 04:31 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Option Exercise	3.30	50,000	165,000	230,418	Sep 11 09:45 PM
Zelnick Kaufman Beth	Chief Legal Officer	Sep 09 '25	Sale	13.41	50,000	670,264	180,418	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Option Exercise	1.45	41,121	59,625	218,111	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Option Exercise	1.45	12,876	18,670	189,866	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 11 '25	Sale	13.08	41,121	537,863	176,990	Sep 11 09:45 PM
Hurlburt Elizabeth	Chief Operating Officer	Sep 09 '25	Sale	13.51	12,876	173,955	176,990	Sep 11 09:45 PM
Zelnick Kaufman Beth	Officer	Sep 09 '25	Proposed Sale	13.46	50,000	673,000		Sep 09 04:52 PM
Hurlburt Elizabeth	Officer	Sep 09 '25	Proposed Sale	13.50	53,997	728,959		Sep 09 04:51 PM
David Matthew T	Former Officer	Sep 03 '25	Proposed Sale	14.50	300,000	4,350,000		Sep 03 04:32 PM
Lefkowitz Steven W	Director	Apr 02 '25	Option Exercise	4.03	20,000	80,600	120,498	Apr 03 04:30 PM
Todisco Joseph	Chief Executive Officer	Apr 01 '25	Option Exercise	3.38	59,170	199,995	530,721	Apr 02 07:00 AM
Hurlburt Elizabeth	EVP	Nov 14 '24	Option Exercise	4.48	140,027	627,727	185,424	Nov 18 08:37 PM
Hurlburt Elizabeth	EVP	Nov 14 '24	Sale	11.18	140,027	1,565,670	45,397	Nov 18 08:37 PM
Hurlburt Elizabeth	Officer	Nov 14 '24	Proposed Sale	11.12	140,027	1,556,416		Nov 14 04:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRMD

CorMedix Inc

Upgrade your FINVIZ experience